AMLX Amylyx Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMLX

Price (delayed)

$22.48

Market cap

$2.5B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.41

Enterprise value

$2.46B

?
Relative Growth: Rel. Growth: 33
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 9
Highlights
Amylyx Pharmaceuticals's revenue has soared by 100% YoY
AMLX's gross profit has surged by 100% year-on-year
The equity rose by 42% year-on-year but it has declined by 12% since the previous quarter
The quick ratio has increased by 40% YoY but it has decreased by 32% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://amylyx.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of AMLX

AMLX stock price

How has the Amylyx Pharmaceuticals stock price performed over time
Intraday
-3.73%
1 week
-7.07%
1 month
29.12%
1 year
170.84%
YTD
86.09%
QTD
25.17%

Financial performance

How have Amylyx Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$162.1M
Net income
-$152.09M
Gross margin
N/A
Net margin
N/A
Amylyx Pharmaceuticals's revenue has soared by 100% YoY
AMLX's gross profit has surged by 100% year-on-year
Amylyx Pharmaceuticals's net income has increased by 19% YoY
The company's operating income rose by 18% YoY

Price vs fundamentals

How does AMLX's price correlate with its fundamentals

Growth

What is Amylyx Pharmaceuticals's growth rate over time

Valuation

What is Amylyx Pharmaceuticals stock price valuation
P/E
N/A
P/B
10.45
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
AMLX's EPS is up by 43% year-on-year and by 4.7% since the previous quarter
AMLX's P/B is 161% above its 5-year quarterly average of 4.0 and 90% above its last 4 quarters average of 5.5
The equity rose by 42% year-on-year but it has declined by 12% since the previous quarter
Amylyx Pharmaceuticals's revenue has soared by 100% YoY

Efficiency

How efficient is Amylyx Pharmaceuticals business performance
Amylyx Pharmaceuticals's ROE has increased by 49% YoY and by 5% from the previous quarter
Amylyx Pharmaceuticals's ROA has increased by 45% YoY and by 4.3% from the previous quarter
The company's return on invested capital rose by 16% QoQ and by 16% YoY

Dividends

What is AMLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMLX.

Financial health

How did Amylyx Pharmaceuticals financials performed over time
The quick ratio has increased by 40% YoY but it has decreased by 32% from the previous quarter
The current ratio is up by 39% year-on-year but it has declined by 32% since the previous quarter
Amylyx Pharmaceuticals's debt is 98% less than its equity
AMLX's debt to equity has dropped by 50% year-on-year
The equity rose by 42% year-on-year but it has declined by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.